Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare Accredits GenUs to Use CodeLink Platform for Gene-Expression Service

NEW YORK, Nov. 18 (GenomeWeb News) - GE Healthcare accredited GenUs BioSystems to provide gene-expression services using the conglomerate's CodeLink platform, a GenUs spokesperson said today.

 

GenUs "is the only certified CodeLink laboratory focused solely on gene expression experimentation," said Jeff Bergau, a spokesperson for GenUs.

 

The company will use CodeLink for both gene expression and "DNA-based" experiments, according to a GenUs statement.

 

Scott Magnuson, president of GenUs, helped develop the CodeLink technology while he was head of genomics and bioinformatics for Motorola Life Sciences. He later left the company after it was bought by Amersham to begin GenUs in April, 2003, according to BioArray News, a GenomeWeb New publication.

 

The CodeLink platform became the property of GE Healthcare when the company acquired Amersham in April.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.